MedTrace Logo

Assessing The Impact Of Incorporating Charlson Comorbidity Scores On Patient Anxiety And Satisfaction

NCT03950180 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 277

Last updated 2019-06-12

No results posted yet for this study

Summary

The purpose of this study was to determine whether providing patients with life expectancy (LE) information in the form of their Prostate Cancer Comorbidity Index (PCCI) scores impacted their decisional conflict or anxiety about prostate cancer or death.

Conditions

Interventions

OTHER

Prostate Cancer Comorbidity Index (PCCI) score

Life expectancy information

Sponsors & Collaborators

  • Virginia Mason Hospital/Medical Center

    collaborator OTHER

  • Axio Research Corporation

    collaborator INDUSTRY

  • Benaroya Research Institute

    lead OTHER

Principal Investigators

  • John M Corman, MD · Benaroya Research Institute at Virginia Mason

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-12
Primary Completion
2015-02-27
Completion
2015-02-27

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03950180 on ClinicalTrials.gov